An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy

The existing treatment regime against tuberculosis is not adequate, and novel therapeutic interventions are required to target Mycobacterium tuberculosis (Mtb) pathogenesis. We report Pranlukast (PRK) as a novel allosteric inhibitor of Mtb's arginine biosynthetic enzyme, Ornithine acetyltransfe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishra, Archita, Mamidi, Ashalatha S, Rajmani, Raju S, Ray, Ananya, Roy, Rajanya, Surolia, Avadhesha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887547/
https://www.ncbi.nlm.nih.gov/pubmed/29483133
http://dx.doi.org/10.15252/emmm.201708038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887547/
https://www.ncbi.nlm.nih.gov/pubmed/29483133
http://dx.doi.org/10.15252/emmm.201708038

Ejemplares similares